Experimental discovery of T-cell epitopes: Combining the best of classical and contemporary approaches

Expert Review of Vaccines

Volumn 6, Issue 4, 2007, Pages 605-615

  Scharnagl, Nicole C ^a   Klade, Christoph S ^a  

^a INTERCELL AG   (Austria)

Author keywords

Chronic disease; HLA; T cell epitope; Vaccine

Indexed keywords

ANTIGEN; EPITOPE; HLA C ANTIGEN; HLA DP ANTIGEN; HLA DQ ANTIGEN; HLA DR3 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; T CELL EPITOPE; UNCLASSIFIED DRUG; VACCINE;

ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; CD8+ T LYMPHOCYTE; CELL CLONING; CELL SURFACE; DENDRITIC CELL; DRUG DESIGN; ENZYME LINKED IMMUNOSPOT ASSAY; EXPERIMENTAL MODEL; HUMAN; IMMUNOASSAY; METHODOLOGY; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN STRUCTURE; REVIEW; SENSITIVITY ANALYSIS; T LYMPHOCYTE; TRANSGENIC MOUSE; VIRUS GENE;

ANIMALS; ANTIGEN PRESENTATION; CD4-POSITIVE T-LYMPHOCYTES; DRUG DESIGN; EPITOPES, T-LYMPHOCYTE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; LEUKOCYTES, MONONUCLEAR; MICE; MICE, TRANSGENIC; T-LYMPHOCYTES, CYTOTOXIC;

EID: 34548009094     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.6.4.605     Document Type: Review

References (60)

1. Schepers K, Arens R, Schumacher TN. Dissection of cytotoxic and helper T cell responses. Cell. Mol. Life Sci. 62(23), 2695-2710 (2005).
2. Nelson JW. A call to arms: the cytokine selection service. Sci. STKE 2001(91), PE2 (2001).
3. Schulze-Koops H, Kalden JR. The balance of Th1/Th2 cytokines in rheumatoid arthritis. Best Pract. Res. Clin. Rheumatol. 15(5), 677-691 (2001).
4. Wodarz D, Jansen VA. The role of T cell help for anti-viral CTL responses. J. Theor. Biol. 211(4), 419-432 (2001).
5. Kidd P. Th1/Th2 balance: the hypothesis, its limitations, and implications for health and disease. Altern. Med. Rev. 8(3), 223-246 (2003).
6. Kopec A, Panaszek B, Fal AM. Intracellular signaling pathways in IgE-dependent mast cell activation. Arch. Immunol. Ther. Exp. (Warsz.) 54(6), 393-401 (2006).
7. Simon D, Braathen LR, Simon HU. Anti-interleukin-5 antibody therapy in eosinophilic diseases. Pathobiology 72(6), 287-292 (2005).
8. +) T cells: multiple pathways on the road. J. Cell. Physiol. 211(3), 590-597 (2007).
9. Loureiro J, Ploegh HL. Antigen presentation and the ubiquitin-proteasome system in host-pathogen interactions. Adv. Immunol. 92, 225-305 (2006).
10. Sioud M. An overview of the immune system and technical advances in tumor antigen discovery and validation. Methods Mol. Biol. 360, 277-318 (2007).
11. Takahashi H. Antigen presentation in vaccine development. Comp. Immunol. Microbiol. Infect. Dis. 26(5-6), 309-328 (2003).
12. Shen L, Rock KL. Priming of T cells by exogenous antigen cross-presented on MHC class I molecules. Curr. Opin. Immunol. 18(1), 85-91 (2006).
13. Cao K, Hollenbach J, Shi X, Shi W, Chopek M, Fernandez-Vina MA. Analysis of the frequencies of HLA-A, B, and C alleles and haplotypes in the five major ethnic groups of the United States reveals high levels of diversity in these loci and contrasting distribution patterns in these populations. Hum. Immunol. 62(9), 1009-1030 (2001).
14. Ovsyannikova IG, Jacobson RM, Poland GA. Variation in vaccine response in normal populations. Pharmacogenomics 5(4), 417-427 (2004).
15. Sette A, Sidney J. Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism. Immunogenetics 50(3-4), 201-212 (1999).
16. Sylvester-Hvid C, Nielsen M, Lamberth K et al. SARS CTL vaccine candidates; HLA supertype-, genome-wide scanning and biochemical validation. Tissue Antigens 63(5), 395-400 (2004).
17. + T cells by a single peptide with dual MHC class I and class II specificities: a new strategy for vaccine design. Cancer Res. 62(13), 3630-3635 (2002).
18. Zwaveling S, Ferreira Mota SC, Nouta J et al. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J. Immunol. 169(1), 350-358 (2002). • Excellent paper demonstrating the immunogenicity and efficacy of peptide vaccination. Confirmation of the pharmacological advantage of longer peptides over minimal cytotoxic T lymphocyte-epitope peptides.
19. Valmori D, Levy F, Godefroy E et al. Epitope clustering in regions undergoing efficient proteasomal processing defines immunodominant CTL regions of a tumor antigen. Clin. Immunol. 122(2), 163-172 (2007).
20. Khan AM, Heiny AT, Lee KX et al. Large-scale analysis of antigenic diversity of T-cell epitopes in dengue virus. BMC Bioinformatics 7(Suppl. 5), S4 (2006).
21. van der Burg SH, Bijker MS, Welters MJ, Offringa R, Melief CJ. Improved peptide vaccine strategies, creating synthetic artificial infections to maximize immune efficacy. Adv. Drug Deliv. Rev. 58(8), 916-930 (2006).
22. Ali FR, Larche M. Peptide-based immunotherapy: a novel strategy for allergic disease. Expert Rev. Vaccines 4(6), 881-889 (2005).
23. Elsawa SF, Rodeberg DA, Celis E. T-cell epitope peptide vaccines. Expert Rev. Vaccines 3(5), 563-575 (2004).
24. Scheibenbogen C, Letsch A, Schmittel A, Asemissen AM, Thiel E, Keilholz U. Rational peptide-based tumour vaccine development and T cell monitoring. Semin. Cancer Biol. 13(6), 423-429 (2003).
25. Arnon R, Ben-Yedidia T. Old and new vaccine approaches. Int. Immunopharmacol. 3(8), 1195-1204 (2003).
26. Firbas C, Jilma B, Tauber E et al. Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: a randomized, placebo controlled trial for dose optimization in 128 healthy subjects. Vaccine 24(20), 4343-4353 (2006). •• Clearly designed clinical trial in 128 HLA-A2 positive healthy volunteers for dose optimization of a peptide-based T-cell vaccine for therapy of chronic hepatitis C virus infection. Validated T-cell assays including IFN-γ ELIspot, lymphoproliferation and HLA tetramer analysis, were extensively applied as a read-out of vaccine immunogenicity.
27. Suhrbier A. Polytope vaccines for the codelivery of multiple CD8 T-cell epitopes. Expert Rev. Vaccines 1(2), 207-213 (2002).
28. + T cell epitope from the C1 domain of factor VIII. J. Thromb. Haemost. 3(5), 991-1000 (2005).
29. Keilholz U, Martus P, Scheibenbogen C. Immune monitoring of T-cell responses in cancer vaccine development. Clin. Cancer Res. 12(7 Pt 2), S2346-S2352 (2006). • Comprehensive review on state-of-the-art immunological monitoring. The methodology described is not only applicable to cancer vaccines but to clinical trials that need a T-cell immunity read-out in general.
30. Wang RF. Tumor antigens discovery: perspectives for cancer therapy. Mol. Med. 3(11), 716-731 (1997).
31. Lemmel C, Stevanovic S. The use of HPLC-MS in T-cell epitope identification. Methods 29(3), 248-59 (2003).
32. Kessler JH, Beekman NJ, Bres-Vloemans SA et al. Efficient identification of novel HLA-A(*)0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis. J. Exp. Med. 193(1), 73-88 (2001). • Important step forward in replicating T-cell antigen processing and presentation in vitro. In addition to binding of peptides to HLA molecules their intracellular processing was also approached experimentally by in vitro proteasomal digest with a mass spectrometric read-out of resulting peptide fragments.
33. Tenzer S, Peters B, Bulik S et al. Modeling the MHC class I pathway by combining predictions of proteasomal cleavage, TAP transport and MHC class I binding. Cell. Mol. Life Sci. 62(9), 1025-1037 (2005).
34. Hakenberg J, Nussbaum AK, Schild H et al. MAPPP: MHC class I antigenic peptide processing prediction. Appl. Bioinformatics 2(3), 155-158 (2003).
35. Weidanz JA, Piazza P, Hickman-Miller H et al. Development and implementation of a direct detection, quantitation and validation system for class I MHC self-peptide epitopes. J. Immunol. Methods 318(1-2), 47-58 (2007).
36. Kern F, Faulhaber N, Frommel C et al. Analysis of CD8 T cell reactivity to cytomegalovirus using protein-spanning pools of overlapping pentadecapeptides. Eur. J. Immunol. 30(6), 1676-1682 (2000). •• Pioneering approach in the use of pools of overlapping 15-meric peptides to comprehensively analyse T-cell responses against the cytomegalovirus antigen pp65 directly ex vivo.
37. Maecker HT, Dunn HS, Suni MA et al. Use of overlapping peptide mixtures as antigens for cytokine flow cytometry. J. Immunol. Methods 255(1-2), 27-40 (2001).
38. Tobery TW, Wang S, Wang XM et al. A simple and efficient method for the monitoring of antigen-specific T cell responses using peptide pool arrays in a modified ELISpot assay. J. Immunol. Methods 254(1-2), 59-66 (2001).
39. +)-T-cell responses against hepatitis C virus reveals multiple unpredicted specificities. J. Virol. 76(12), 6104-6113 (2002). •• This paper, together with [40] represents the first published comprehensive analysis of T-cell epitopes within the hepatitis C virus genome. Importantly, not only was the feasibility of such a comprehensive approach using patient peripheral blood mononuclear cells directly ex vivo demonstrated, but results also included a number of novel T-cell epitopes not predicted by standard algorithms.
40. + T-helper-cell responses in resolved hepatitis C virus infection. J. Virol. 76(24), 12584-12595 (2002). •• This paper, together with [39] represents the first published comprehensive analysis of T-cell epitopes within the hepatitis C virus genome.
41. Lauer GM, Barnes E, Lucas M et al. High resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection. Gastroenterology 127(3), 924-936 (2004).
42. + T cell subpopulations. AIDS Res. Hum. Retroviruses 23(3), 471-476 (2007).
43. Nino-Vasquez JJ, Allicotti G, Borras E et al. A powerful combination: the use of positional scanning libraries and biometrical analysis to identify cross-reactive T cell epitopes. Mol. Immunol. 40(14-15), 1063-1074 (2004).
44. Aichinger G, Karlsson L, Jackson MR et al. Major histocompatibility complex class II-dependent unfolding, transport, and degradation of endogenous proteins. J. Biol. Chem. 272(46), 29127-29136 (1997).
45. Abstracts of the 55th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, Massachusetts, USA, October 29-November 2004. Hepatology 40(4 Suppl. 1), 162A-771A (2004).
46. Klade CS, Otava O, Vytvytska O et al. A comprehensive analysis of the T cell response against conserved regions of HCV genotypes 1, 2 and 3. 1(Suppl.), 695A (2004).
47. + T cell epitopes from complex antigens. J. Immunol. 166(11), 6665-6670 (2001).
48. Sylvester-Hvid C, Kristensen N, Blicher T et al. Establishment of a quantitative ELISA capable of determining peptide - MHC class I interaction. Tissue Antigens 59(4), 251-258 (2002).
49. Welsh RM, Kim SK, Cornberg M, Clute SC, Selin LK, Naumov YN. The privacy of T cell memory to viruses. Curr. Top. Microbiol. Immunol. 311, 117-153 (2006).
50. Singh RA, Rodgers JR, Barry MA. The role of T cell antagonism and original antigenic sin in genetic immunization. J. Immunol. 169(12), 6779-6786 (2002).
51. Bachmaier K, Penninger JM. Chlamydia and antigenic mimicry. Curr. Top. Microbiol. Immunol. 296, 153-163 (2005).
52. +)-cell responses to vaccinia virus. Nat. Biotechnol. 24(7), 817-819 (2006).
53. Peters B, Sette A, Integrating epitope data into the emerging web of biomedical knowledge resources. Nat. Rev. Immunol. 7(6), 485-490 (2007).
54. Schellack C, Prinz K, Egyed A et al. IC31, a novel adjuvant signaling via TLR9, induces potent cellular and humoral immune responses. Vaccine 24(26), 5461-5472 (2006).
55. Klade CS, Schalich J, Vytvytska O et al. Method for Isolating Ligands. PCT: WO 03/073097 A2.
56. Buschle M, Habel A, Klade CS et al. Method for Isolating Hepatitis C Peptides. PCT: WO 2004/024182 A2.
57. Buschle M, Frisch J, Kade CS, Lingnau K, Zauner W, Zettlmeissl G. HCV Vaccines. PCT: WO 2005/004910 A2. 201 IMGT/HLA database www.ebi.ac.uk/imgt/hla/ stats.html
58. EpiVax Inc., Informatics and Immunology http://epivax.com/matriarch/ MultiPiecePage.asp_Q_PageID_E_5_A_PageName_E_TechnicalPlatform
59. Immunomics. iTopia™ Epitope Discovery System www.immunomics.com/ epitope.asp
60. Proimmune www.proimmune.com/ecommerce/page.php?page=reveal